Navigation Links
Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
Date:2/7/2013

CRANBURY, N.J., Feb. 7, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 15th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15th Annual BIO CEO & Investor Conference will take place February 11-12 at the Waldorf=Astoria in New York City.

Carl Spana , Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs on Monday, February 11, 2013 at 11:00 a.m. ET.

Palatin Technologies has reported positive top-line results in its recently completed Phase 2B clinical trial with bremelanotide for treatment of female sexual dysfunction, and is preparing for an end-of-Phase 2 meeting with the Food and Drug Administration in anticipation of commencing Phase 3 trials. A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com. The live audio broadcast will be available through February 18, 2013.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

ABOUT THE BIO CEO & INVESTOR CONFERENCE
The 15th Annual BIO CEO & Investor Conference i
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
3. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
4. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
5. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
6. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
7. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
8. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
9. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
10. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
11. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015 The American Brain Tumor ... for its Discovery Research Grant program. LOIs are due ... noon CDT. Discovery Grants are one-year, $50,000 ... potential to change current diagnostic or treatment paradigms for ... encourage novel research at its earliest stages, in the ...
(Date:9/1/2015)... 2015 Prostate cancer is the second ... men. One in seven men will be diagnosed ... are diagnosed annually. That said, not every diagnosis ... new technique, MRI Fusion Biopsy, to more accurately ... only the affected areas and monitoring areas ...
(Date:9/1/2015)... ... ... In her thought provoking debut novel ‘ Ebola Vaccine Wars ’ (eBookIt.com; ... an Ebola pandemic that is on the cusp of wiping out humanity. Venice introduces ... counterterrorism, and who continues to appear in this series of books by Venice. ...
(Date:9/1/2015)... Poway, CA (PRWEB) , ... September 01, 2015 ... ... Equine Cervical Facet joint disease. , Equine cervical facet joint problems can ... joints gradually enlarge, and can cause impingement of nerve roots or of the ...
Breaking Biology Technology:American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3
... 2011 SARcode Corporation has named Todd Creech as ... effective February 1, 2011. Creech has been fulfilling both ...   (Photo: http://photos.prnewswire.com/prnh/20110214/FL47222LOGO ) ... experience in finance and leadership roles and has demonstrated ...
... 2011 Aperion Biologics, Inc. announced the enrollment and ... trial of its Z-Lig™ Anterior Cruciate Ligament Reconstruction (ACLR) ... knee.  The primary objective of the multicenter study is ... of Z-Lig in the reconstruction of patients, knees with ...
... 11, 2011 Genesis Biopharma, Inc. (OTC ... developing targeted cancer therapies, today announced that Anthony J. ...  Mr. Cataldo succeeds Robert Brooke, who now serves as ... Company named Michael Handelman as Chief Financial Officer, Treasurer ...
Cached Biology Technology:Todd A. Creech Named Chief Financial Officer and Vice President of Business Development for SARcode Corporation 2Todd A. Creech Named Chief Financial Officer and Vice President of Business Development for SARcode Corporation 3Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction 2Genesis Biopharma Announces Management and Board Changes 2Genesis Biopharma Announces Management and Board Changes 3
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... cell scientists have a new theory for how stem ... development. A cell,s fate, the researchers found, is determined ... best known for its role in,inflammation and pain. The ... could potentially,make liver and pancreas cells easier to generate ...
... news release is available in German . ... of amino acids and are vital for all cell processes. Proteases ... they cut other proteins at given positions and thereby execute important ... length or breaking proteins apart they, for example, activate or deactivate ...
... Professor of Entomology at North Carolina State University (NCSU), ... lecture at Entomology 2014, the 62nd Annual Meeting of ... in Portland, Oregon, November 16-19, 2014. The topic ... L. Rabb, a professor of entomology at NCSU and ...
Cached Biology News:Harvard scientists find cell fate switch that decides liver, or pancreas? 2Two new weapons in the battle against bacteria 2NCSU entomologist Fred Gould to present 2014 Founders' Memorial Lecture 2
XBP-1 (F-4)...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
pETDuet-1 is designed for the coexpression of two target genes....
...
Biology Products: